UBS remains bullish on Eli Lilly’s future thanks to surging demand for its obesity and diabetes treatments. UBS predicts Zepbound sales could exceed market expectations by roughly 15%. Meanwhile, ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

While Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Eli Lilly stock currently trades below its 50-week average, offering a strong entry point despite continued dominance in ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

A cyberattack on Synnovis has been linked to a patient's death at King's College Hospital, marking a serious hacking ...

These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...